Oxidative stress in diabetic neuropathy: source of reactive oxygen species

Mohit Chopra, Kirti Kaul, Joanna Tarr, Ruhul Choudhury, Eva M. Kohner, Rakesh Chibber
Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter, St Luke’s Campus, Exeter, UK

Abstract

Diabetic neuropathy is a common diabetic complication. Oxidative stress (OS) is a significant mediator in the development of diabetic neuropathy. Exposing neurons to hyperglycaemia increases OS, inhibits neurite outgrowth and causes apoptosis. In the present study we explore the role of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase vs. mitochondrial reactive oxygen species (mtROS) in diabetic neuropathy. Human neuroblastoma SH-SY5Y cells were treated with high glucose (25 mM) or normal glucose (5.5 mM) in the presence and absence of the specific NADPH oxidase inhibitor gp91ds-tat (6 days). Caspase activity, intracellular ROS, mtROS production, mitochondrial membrane potential (ΔΨm) and NADPH oxidase activity were measured. Neurite outgrowth and neurites/cell were analysed using Image J software. Chronic exposure to high glucose increased caspases activity and cytoplasmic but not mtROS levels, and reduced the number of neurites/cell and the neurite outgrowth compared to normal glucose. Co-treatment with gp91ds-tat reversed the increased levels of ROS and prevented glucose-induced neurite inhibition. ΔΨm and mtROS levels were unaffected at the end of the treatment. The current study demonstrates that NADPH oxidase, and not the mitochondria derived ROS, is responsible for the induction of apoptosis in SH-SY5Y cells. The use of NADPH oxidase inhibitors may prove to be of therapeutic value in the treatment of diabetic neuropathy.

Introduction

Diabetes is a world epidemic with figures suggesting that more than 366 million people are currently living with diabetes and this figure is expected to rise to 532 million by 2030. At least 50% of these patients will develop neuropathy, a leading cause of non-traumatic lower limb amputations and autonomic failure in diabetic patients.1 The natural progression of diabetic neuropathy involves nerve fiber loss, demyelination and axonal degeneration of myelinated fibres.2 The vast majority of patients with clinical diabetic neuropathy have a distal symmetrical form of the disorder that progresses following a fiber-length-dependent pattern, with sensory and autonomic manifestations predominating. Patients with long-standing diabetes mellitus, develop focal and multifocal neuropathies that include cranial nerve involvement and limb and truncal neuropathies.3

Although, the pathogenesis of diabetic neuropathy remains unclear, the Diabetic Control and Complications Trial and the United Kingdom Prospective Diabetes Study have confirmed the central role of hyperglycaemia in the disease process.4,5 The major pathways of glucose metabolism that have been implicated in the development of microvascular complications include, i) increased flux through the polyl pathway, ii) non-enzymatic glycation of proteins yielding to the formation of advanced glycation end-products (AGE’s), iii) activation of Protein Kinase C (PKC) and iv) increased hexosamine pathway activity. An increased production of reactive oxygen species (ROS) such as superoxide radical (O2−) and hydroxyl radical (OH·), has been suggested as a unified process that links the above pathways of hyperglycaemia induced damage.6 There is evidence from various studies suggesting that increased production of ROS and oxidative stress leads to the development and progression of diabetic neuropathy.7,8 Exposing neurons to elevated glucose increases oxidative stress which induces the production of ROS that triggers a mechanism that leads to apoptosis and inhibits neurite outgrowth.9,10 The lack of normal neurite outgrowth might reflect the dysfunction of molecules or proteins that are important for maintaining a normal neuronal process.11

Oxidative stress is the imbalance between oxidants and antioxidants in favour of the oxidants, potentially leading to damage. Numerous enzyme systems produce ROS in mammalian cells, including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase,12 uncoupled nitric oxide (NO) synthase and the mitochondrial electron transport chain.13,14 A mitochondrial-dependent process has been suggested as a central mediator of oxidative stress in diabetic complications.15 We have recently exhibited that NADPH oxidase and not mitochondria - derived ROS is responsible for the accelerated apoptosis of pericytes in diabetic retinopathy (DR).16 Retinal capillary pericytes pre-treated with a NADPH oxidase inhibitor, apocynin reversed glucose-induced apoptosis, ROS production and N–(carboxymethyl) lysine (CML) production.17 The role of NADPH oxidase has been previously demonstrated in DR and diabetic nephropathy.17,18 NADPH oxidase has been shown to be responsible for the ROS production mediating the cerebrovascular dysfunction induced by the amyloid-β peptide and NADPH oxidase deficient mice exhibit reduced injury after stroke.19,20

In the present study, we used SH-SY5Y neuroblastoma cells to explore the role of NADPH oxidase vs. mitochondria-derived ROS in the development of diabetic neuropathy (DN) by using a specific NADPH oxidase inhibitor, gp91 ds-tat. The peptide-inhibitor gp91ds-tat prevents the assembly of NADPH oxidase subunits, thereby inhibiting the activity of the enzyme. Here we show that high glucose induced ROS is derived from NADPH oxidase and is involved in the apoptosis of SH-SY5Y neuroblastoma cells.

Materials and Methods

Materials

RPMI - 1640 glucose free medium, foetal bovine serum, penicillin, streptomycin, phosphate buffered saline (PBS), Cytochrome C,
Diphenyleneiodonium (DPI), NADPH oxidase were purchased from Sigma (Poole, UK). Tissue culture plastics were obtained from Sarstedt (Leicester, UK) and Greiner Bio-one (Gloucestershire, UK). Carboxy-H$_2$DCFDA and MitoSOX™ were purchased from Invitrogen (Paisley, UK). NADPH oxidase inhibitor, gp91ds-tat scrambled and unscrambled was purchased from Anaspec (California, USA). Homogeneous Caspases assay was purchased from Roche Diagnostics (Indianapolis, IN, USA).

**Cell culture and treatment**

The human neuroblastoma cell line, SH-SY5Y were maintained in RPMI-1640 medium supplemented with 5.5mM glucose, 20% fetal bovine serum, 100 U/mL penicillin, and 100 U/mL streptomycin in a humid atmosphere of 5% CO$_2$ and 95% O$_2$ at 37°C. SH-SY5Y cells were harvested using 0.25% trypsin-EDTA and cultured for 24 hours before being treated.

Cells were treated with normal glucose (NG, 5.5 mM), high glucose (HG, 25 mM) and mannitol (25 mM) to act as an osmotic control, for 6 days. Medium was changed every 2 days to maintain the amount of glucose in culture. To treat cells with the NADPH oxidase inhibitor (gp91ds-tat, scrambled and unscrambled, 1 μM), the solution was prepared in HG medium. At the end of the incubation period, conditioned medium was removed and cells were washed with phosphate buffered saline (PBS) and stored at -20°C until use.

**Assessments of caspase activity**

SH-SY5Y cells were cultured on black 96-well cell culture plates for 24h before treatment. Cells were treated with NG (5.5 mM), HG (25 mM) and mannitol (25 mM) for 6 days. Medium was changed every 2 days and at the end of the incubation period the caspase activity was assessed. To assess the activation of caspase proteases during apoptosis, a homogenous caspases activity kit was used which detect caspase 2, 3, 7 and caspase 6, 8, 9 and 10 to a lesser extent, the protocol was followed according to the manufacturer’s instructions (Roche Applied Science, UK). Briefly, 100 μL of caspase substrate (DEVD-Rhodamine 110) was added to each well containing 100 μL of medium and the plate was incubated for 2h at 37°C. Upon the cleavage of the substrate by activated caspases, fluorescence of the released Rhodamine 110 was measured at excitation 485 nm and emission at 520 nm on PHERAstar fluorescence plate reader (BMG Labtech, Germany).

**Measurement of intracellular reactive oxygen species**

The fluorogenic probe, 6 - carboxy-2',7' - dichlorofluorescein diacetate (Carboxy-H$_2$DCFDA) was used to assess the formation of intracellular ROS. Carboxy-H$_2$DCFDA readily

![Figure 1. High glucose treatment increases caspases activity in SH-SY5Y cells. SH-SY5Y cells were treated with 100 μL/well of normal glucose (NG, 5.5 mM), high glucose (HG, 25 mM) and mannitol (25 mM) for 6 days. At the end of the treatment, 100 μL of the caspases substrate was added per well and the plate was incubated for 2h at 37°C. The fluorescence of Rhodamine 110 released from the cleavage of DEVD-Rhodamine 110 by activated caspases was measured. HG treatment increased caspase activity as compared to NG. Data was expressed as mean±standard deviation and presented as percentage of control of 3 separate experiments.***P<0.001.](image1)

![Figure 2. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor reverses glucose induced reactive oxygen species (ROS) levels. SH-SY5Y cells were treated in 96-well plates with normal glucose (NG, 5.5 mM), high glucose (HG, 25 mM), mannitol (25 mM) and the NADPH oxidase specific inhibitor gp91ds-tat (1 μM, scrambled and unscrambled) prepared in HG medium for 6 days. Carboxy-H$_2$DCFDA (10 μM) was added 30 minutes before the end of the treatment, medium was removed, cells washed and 100 μL/well of PBS was added and the fluorescence was measured at excitation 495 nm and the emission 525 nm. HG treatment significantly increased intracellular ROS levels in SH-SY5Y cells compared to cells in NG (***P<0.01, n=3) and this increase in ROS levels was significantly reversed by the co-treatment of cells with the NADPH oxidase inhibitor gp91ds-tat (** P<0.01, n=3). Data was expressed as mean±standard deviation and presented as percentage of control.](image2)
enters cells and measures hydroxyl, peroxyl and other ROS. The probe is first deacetylated by esterases in the cytosol and this product is oxidized by ROS to a highly fluorescent entity, carboxy-2',7'-dichlorofluorescin.

SH-SY5Y cells were cultured in clear bottom black 96-well plates before being treated. Cells were treated with NG (5.5 mM), HG (25 mM) and mannitol to assess the formation of ROS formed under hyperglycaemic conditions. 30 min before the end of the treatment, 10 μM carboxy-H2DCFDA dissolved in cell culture medium was added to the cells. At the end of the treatment period, the media was removed and the cells were washed in PBS and 100 μL of PBS was added in each well. The fluorescence was measured using a PHERAstar plate reader (BMG Labtech, Germany) with the excitation 485 nm and the emission 520 nm.

**Measurement of mitochondrial superoxide levels and mitochondrial membrane potential**

Mitochondrial superoxide levels were analysed using MitoSOX™ red superoxide indicator. MitoSOX™ is live cell permeant and is rapidly and selectively targeted into the mitochondria and once in the mitochondria it is oxidized by superoxide and exhibits red fluorescence.

Tetramethyl Rhodamine Methyl Ester (TMRM) was used as a mitochondrial specific probe to measure the mitochondrial membrane potential (ΔΨm). TMRM is loaded into the cells via the plasma membrane and the dye subsequently sequesters into the mitochondria as the mitochondrial matrix is the most negatively charged part of the cell. Metabolically stressed cells with a loss of ΔΨm exhibit a reduced level of fluorescence intensity.

30 minutes before the end of the treatment, MitoSOX™ (5 μM) or TMRM (1 μM) dissolved in cell culture medium were added to the cells. At the end of the treatment period, the media was removed and the cells were washed in PBS and 100 μL of PBS was added in each well. To assess the mitochondrial superoxide levels using MitoSOX™, the fluorescence was measured at excitation 510 nm and the emission 580 nm and for mitochondrial membrane potential using TMRM, the fluorescence was measured at excitation 530 nm and emission 590 nm using a PHERAstar plate reader (BMG Labtech, Germany).

**Quantification of nicotinamide adenine dinucleotide phosphate oxidase activity**

Measurement of superoxide (O₂⁻) was based on the capacity of NADPH oxidase to reduce ferricytochrome c in ferrocytochrome at pH 7.8 as described earlier.21 Total cell lysate (25 mg protein/experiment), cytochrome c

---

**Figure 3.** High glucose does not affect mitochondrial superoxide levels. SH-SY5Y cells were treated with normal glucose (NG, 5.5 mM), high glucose (HG, 25 mM) and mannitol for 6 days. MitoSOX™ (5 μM) was added 30 min before the end of the treatment and after the incubation, cells were washed with PBS and 100 μL of PBS added per well before the fluorescence was measured at excitation 510 nm and the emission 580 nm. There was no significant difference between NG and HG (n=3). Data expressed as mean±standard deviation and presented as percent of control (Fluorescence/mg protein).

**Figure 4.** High glucose treatment does not affect the mitochondrial membrane potential of SH-SY5Y cells. SH-SY5Y cells were treated with normal glucose (5.5 mM), high glucose (25 mM) and mannitol (25 mM) for 6 days. TMRM (1 μM) was added 30 min before the end of the treatment and at the end of the treatment, cells were washed with PBS and 100 μL of PBS added per well and the fluorescence was measured at excitation 520 nm and emission 560 nm. There was no significant difference in the mitochondrial membrane potential in cells treated with HG compared to NG (n=3). Data expressed as percent of control.
(250 mg/L final concentration) and NADPH (100 mM) were incubated at 37°C for 120 min, either in the presence or absence of diphenyleneiodonium (DPI, 100 mM), an NADPH oxidase inhibitor. The reduction of cytochrome c was calculated by measuring the absorbance at 550 nm. O₂⁻ production in nmol/mg protein was calculated from the difference between absorbance of reactions with and without DPI and the extinction coefficient 21mmol/L/cm.

Assessment of neurite extension and neurites per cell
SH-SY5Y cells were cultured in 6-well cell culture plates for 24hrs. Cells were treated with retinoic acid (RA, 10 µM) to induce neuronal differentiation in conjunction with NG (5.5 mM), HG (25 mM) and mannitol (25 mM).

Statistical analysis
The statistical software Graph Pad Prism version 5.0 was used. One-way Analysis of Variance (ANOVA) and was used to test the significance between variables and a two-tailed Student’s t-test was used to test the significance of paired data. Data are expressed as means ± standard deviation of measurements in the different experiments. Differences between treatment groups were considered statistically significant at P<0.05.

Results
High glucose induces apoptosis in SH-SY5Y cells
The effect of high glucose (HG) on SH-SY5Y cell viability was determined using the Homogeneous Caspase assay kit (Roche, UK). As shown in Figure 1, chronic treatment of SH-SY5Y cells with HG (25 mM) for 6 days resulted in a significant increase in the caspase activity as compared to NG (5.5 mM) (138.60±17.25% versus 100.0±6.18% P<0.001, n=3). Mannitol, an osmotic control had no effect on apoptosis as compared to NG (99.98±11.52% versus 100.00±6.18%, n=3).

Inhibiting nicotinamide adenine dinucleotide phosphate oxidase reversed the glucose-induced increase in reactive oxygen species
Intracellular ROS levels were significantly increased in SH-SY5Y cells treated with HG (25 mM) for 6 days as compared to NG (5.5 mM) treated cells (205.5±20.05% versus 100.0±17.7%) (P<0.01, n=3) (Figure 2).

As seen in Figure 2, co-treatment of cells with the inhibitor of NADPH oxidase, gp91ds-tat (scrambled and unscrambled, 1 µM) in HG (25 mM) medium along with RA. At the end of the incubation period 10 random images were taken (Quantalab software, Nikon TS1000) and neurite-bearing cells were calculated from counts of 10 random fields. ImageJ was used to measure the length of the neurites.

Protein measurement
Total protein was measured using the BCA protein assay kit (Pierce, UK).

Mitochondrial reactive oxygen species levels remained unchanged after exposure to high glucose
Exposure to HG (25 mM) for 6 days did not change the levels of mitochondrial superoxide production in SH-SY5Y cells (Figure 3) (96.63±12.05% compared to normal glucose 100.0±8.7%, n=3).

High glucose treatment did not alter mitochondrial membrane potential
HG treatment did not alter the mitochondrial membrane potential of SH-SY5Y cells (Figure 4) as compared to NG (5.5 mM) after exposure for 6 days (101.3±2.9% compared to 100.0±2.0%, n=3).

Glucose induced an increase in nicotinamide adenine dinucleotide phosphate oxidase activity
SH-SY5Y cells under HG (25 mM) conditions for 6 days increased the superoxide production compared to cells treated with NG (5.5 mM) (0.12±0.03 mM/mg protein versus 0.03±0.03 mM/mg protein). The co-treatment of cells with the NADPH oxidase specific inhibitor, gp91ds-tat reversed the increase in the superoxide production (0.04±0.04 mM/mg protein versus 0.12±0.04 mM/mg protein). The scrambled gp91ds-tat did not alter the increase in superoxide production (0.12±0.06 mM/mg protein versus 0.13±0.04 mM/mg protein) in SH-SY5Y cells (Figure 5).

Figure 5. High glucose increases nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. SH-SY5Y cells were cultured in 30mm² dishes were exposed to normal glucose (NG, 5.5 mM) and high glucose (HG, 25 mM) in the absence and presence of the specific NADPH oxidase inhibitor, gp91 ds-tat (1 µM) for 6 days and lysed. Lysates (50 µg protein), cytochrome c (250 µg/L final concentration) and NADPH (100 µM) were incubated at 37°C for 120 min, either in the presence or absence of diphenyleneiodonium (DPI, 100 mM). The reduction of cytochrome c was measured by reading the absorbance at 550 nm. Superoxide (O₂⁻) production in nmol/mg protein was calculated from the difference between absorbance of samples at 0 and 120 min and the extinction coefficient 21mmol/L/cm. Exposure to HG significantly increases NADPH oxidase (**P<0.001 as compared to NG, n=6-14) activity which is reversed by the addition of the specific NADPH oxidase inhibitor gp91 ds-tat (1 µM) (**P<0.001 as compared to HG, n=6-14). Data is presented as mean±standard deviation of 6-14 separate experiments.
High glucose reduces neurite extension and neuritis per cell

SH-SYSY cells treated with HG (25 mM) for 6 days had a marked reduction in the neurite outgrowth (Figure 6A) (151.00±44.02 pixels versus 285.00±71.98 pixels). In addition, the number of neurites per cell was also significantly lower than cells treated with NG (2.28±0.63 neurites compared to 3.65±0.68 neurites) (Figure 6B). Co-treating the cells with the NADPH oxidase inhibitor gp91 ds-tat (1 μM unscrambled) prevented the inhibition in neurite outgrowth under HG treatment (331±99.46 pixels compared to 151.0±44.02 pixels) and neurites per cell (3.48±0.59 neurites compared to 2.28±0.63 neurites).

Discussion

It is now widely accepted that increased oxidative stress, the imbalance between the production of ROS and the antioxidant capability of the cell, plays a key role in the pathogenesis of DN.22,23 The possible sources for ROS in diabetes include enzymatic pathways, auto-oxidation of glucose, and the mitochondria.7,24 The mitochondrial–dependent processes are considered as a central mediator of oxidative stress in diabetic complications and normalizing mitochondrial ROS prevents glucose induced activation of biochemical pathways involved in the pathogenesis of DN.15 Antioxidants have been shown to prevent the symptoms of DN in experimental systems.25,26 We have recently suggested the role for NADPH oxidase and not mitochondrial-derived ROS (mtROS) in DR. In the present study, we explore the role of NADPH oxidase vs. mitochondrial-derived ROS in the development of DN.

Impairment in signalling mechanisms regulating neuron differentiation is hypothesised to be a main cause of neuronal dysfunction and neurite outgrowth was shown to be significantly retarded in diabetic neurons of streptozotocin induced diabetic rats.10,27 Elevated glucose increases oxidative stress and inhibits neurite outgrowth in retinoic acid promotion of neurite outgrowth in cortical neurons.10 Moreover, recent studies have demonstrated that high glucose induces apoptosis in primary dorsal root ganglion neurons; PC12 cells and SH-SYSY human neuroblastoma cells.28,29 Consistent with these findings, the present study demonstrates that exposure of SH-SYSY cells to HG for 6 days causes increased caspase activity. Increased apoptosis in diabetic neurons involves decreased levels of Bcl-2 and translocation of mitochondrial cytochrome C to the cytosol.30 The induction of apoptosis under HG conditions has also been attributed to the increased production of ROS.16,31


Conclusions

In summary, our data i) highlights the importance of ROS from NADPH oxidase and not the mitochondria in glucose-induced increase in oxidative stress, loss of cell viability and inhibition of neurite outgrowth and neurites per cells, and ii) supports the beneficial effects of antioxidants to prevent oxidative stress and caspases-dependent apoptosis of SH-SYSY cells. Our findings suggest that NADPH oxidase activity may be a therapeutic target for the treatment of progressive diabetic neuropathy.

References


